APA (7th ed.) Citation

Z, R., Y, C., Y, M., Y, W., X, G., J, Z., . . . J, S. (2026). Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 40(4), 733. https://doi.org/10.1007/s40259-026-00776-y

Chicago Style (17th ed.) Citation

Z, Ran, et al. "Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials." BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 40, no. 4 (2026): 733. https://doi.org/10.1007/s40259-026-00776-y.

MLA (9th ed.) Citation

Z, Ran, et al. "Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials." BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, vol. 40, no. 4, 2026, p. 733, https://doi.org/10.1007/s40259-026-00776-y.